Skip to content

Combination Diuretic Therapy for Acute Decompensated Heart Failure

Efficacy and Tolerability of Combination Intravenous Diuretic Therapy Versus Intravenous Loop Diuretic Therapy Alone for the Treatment of Acute Decompensated Heart Failure

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05840536
Acronym
COMBIND-HF
Enrollment
0
Registered
2023-05-03
Start date
2014-05-31
Completion date
2015-10-31
Last updated
2023-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Decompensated Heart Failure

Keywords

heart failure, acute, diuretic, management, renal function, chlorothiazide, furosemide

Brief summary

Patients with heart failure are often admitted to the hospital because they have accumulated excessive amounts of fluid, they become short of breath and congested with fluid. Removing the excess fluid is necessary to improve the patients symptoms and reduce the risk of being re-admitted to the hospital. Diuretics (water pills) are often given through an IV to accelerate the fluid removal. Furosemide is commonly used for fluid removal, however some patients do not respond well to the medication. There are other diuretics available that can work in conjunction with furosemide and increase the rate of fluid removal. The other water pills have slightly different mechanisms of action in the body compared to furosemide and when combined they may increase fluid removal. The investigators hypothesize that adding chlorothiazide to furosemide will result in quicker and more effective fluid removal in heart failure patients.

Detailed description

The investigators will randomly assign patients to receive either furosemide alone or furosemide in combination with chlorothiazide when they are admitted to the hospital with acute heart failure and excessive volume. All patients will be monitored for rate of fluid removal, improvement in symptoms, and side-effects of the medications.

Interventions

DRUGFurosemide plus Chlorothiazide

Patients will receive lasix infusion starting at 5mg/hr along with a bolus dose of chlorothiazide 250mg at the initiation of the protocol. The lasix infusion can be titrated to 10mg after 12hrs based on volume of diuresis. This arm will also receive 250mg bolus doses of chlorothiazide every 12hrs for the duration of the study. Intravenous (IV) lasix infusion at 5mg/hr plus IV boluses of diuril every 12 hrs.

DRUGFurosemide

Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.

Sponsors

Ochsner Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Acute Decompensated Heart Failure - by at least 1 symptom (dyspnea, exercise intolerance, weight gain, edema) and at least 1 sign (chest x-ray (CXR), elevated brain natriuretic peptide (BNP), rales, elevated jugular venous pressure (JVP)). * History of Congestion Heart Failure (CHF) with chronic loop diuretic use for at least the past 4 weeks * Echocardiogram in the past 12 months (to document Ejection fraction (EF))

Exclusion criteria

* Chronic Kidney Disease (CKD) or Acute Kidney Injury (AKI) - Cr \>2.5 mg/dL * Ventricular assist device * Cardiogenic shock * Need for mechanical or vasopressor support on admission * Significant co-morbidities: Chronic Obstructive Pulmonary Disease, pneumonia, pulmonary embolism * History of pulmonary hypertension (PAH) (World Health Organization (WHO) group I primary PAH) * Acute Ischemia / post-intervention (Coronary Artery Bypass Graft, Percutaneous Coronary Interventions) in the past 90 days

Design outcomes

Primary

MeasureTime frameDescription
Volume of DiuresisDuring Index Hospitalization at 72 hoursTotal volume of urine output will be collected during the first 72 hours of admission.
Change in Serum Creatinine from BaselineDuring Index Admission up to 120 hoursChange in serum creatinine from baseline after 72 hours of diuresis

Secondary

MeasureTime frameDescription
Total Weight LossFrom date of index hospitalization until 72 hours after diuresis
Relief of SymptomsFrom date of index hospitalization until 72 hours after diuresisUsing the five-point Likert scale for dyspnea which ranges from 1-5 where the lower the score the better the outcome
HypokalemiaFrom date of index hospitalization until 72 hours after diuresis
Potassium Replacement RequirementsFrom date of index hospitalization until date of discharge from hospital, assessed up to 1 week
Adverse EventsFrom date of index hospitalization until date of discharge from hospital, assessed up to 1 weekHypotension, dizziness, syncope, acute renal failure, arrhythmia
Length of StayFrom date of index hospitalization until date of discharge from hospital, assessed up to 1 week
Electrolyte DisturbancesFrom date of index hospitalization until 72 hours after diuresisMagnesium, Phosphorous

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026